Available Until 12/12/2023
VIEW CART

Oncology Pharmacy Clinical Sessions (Cert # L229380)

ACPE Numbers: Various – see listing below
Pre-Sale Date: N/A
Content Release Date: 12/14/2022
Expiration Date: 12/12/2023
Activity Type: Application-based
CE Credits: 4.0 (BPS and ACPE) contact hours
Activity Fee: $150 (ASHP member); $250 (non-member)

Activity Overview

The Clinical Sessions Package is intended for board certified pharmacists in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS). Using a case-based approach, the activities provide high-level, interactive discussions on contemporary and emerging issues oncology. 

The Oncology Clinical Sessions Recertification Package consists of 2 activities (see table below) and provides up to 4.0 contact hours of continuing pharmacy education and/or recertification credit.   

These activities are part of the ASHP and ACCP professional development program for BCOP recertification approved by the BPS.

These activities were presented as part of the 2022 Midyear Clinical Meeting and ACCP Annual Meeting. Learners who claimed ACPE credit for these activities as part of that meeting, should not claim ACPE credit again.

The American Society of Health-System Pharmacists and the American College of Clinical Pharmacy are accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

These recertification activities are intended for board certified pharmacists seeking to update their knowledge and skills in:

  • ctDNA and minimal residual disease
  • Bleeding disorders

Recertification Credit

Board certified pharmacists are eligible to receive up to 4.0 contact hours of recertification credit for completing this package. To earn recertification credit, learners must review the activity content and successfully complete the online assessments by the deadline. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed. You are allowed only one attempt to successfully complete this assessment. 

Recertification credit is earned in the calendar year in which you pass the recertification assessment.

Learning Activity

ACPE Number

Contact Hours

Recertification Assessment

Taking a Deeper Dive: The Utilization of ctDNA and Minimal Residual Disease (MRD) to Assess Anticancer Therapeutic Response in Cancer (BCOP)

 0217-9999-22-070-H01-P 2.0 ACPE/BPS

80%

The Alphabet Soup of Bleeding Disorders: Background and Treatment Updates in ITP, TTP, HUS, and DIC (BCOP)

0217-9999-22-071-H01-P

2.0 ACPE/BPS

81%

Taking a Deeper Dive: The Utilization of ctDNA and Minimal Residual Disease (MRD) to Assess Anticancer Therapeutic Response in Cancer
ACPE #: 0217-9999-22-070-H01-P

  • Compare differences in the technologies utilized in solid tumor genomic profiling (tissue vs. plasma).
  • Assess the utility of measuring serial plasma cell-free (ctDNA) in therapy response assessment.
  • Describe minimal residual disease (MRD) testing methods.
  • Evaluate the impact and challenges of MRD in hematologic malignancies.

The Alphabet Soup of Bleeding Disorders: Background and Treatment Updates in ITP, TTP, HUS, and DIC
ACPE #: 0217-9999-22-071-H01-P

  • Illustrate understanding of the basic pathophysiology of immune thrombocytopenia (ITP), thrombotic thrombocytopenic purpura (TTP), hemolytic uremic syndrome (HUS), and disseminated intravascular coagulation (DIC) and their associated drug therapies.
  • Examine patients’ medication lists to identify common medications (including cancer treatments, immunotherapies, and drugs from other classes) implicated in the development of bleeding disorders.
  • Compare and contrast pharmacologic standard-of-care and new therapies for the treatment of immune thrombocytopenia (ITP), thrombotic thrombocytopenic purpura (TTP), hemolytic uremic syndrome (HUS), and disseminated intravascular coagulation (DIC).
  • Show the relationship between COVID-19 (and COVID-19 vaccinations) and bleeding disorders, and how to approach the treatment of these disorders.
  • Demonstrate the critical role of the clinical pharmacist in the procurement and administration of pharmacologic therapies used to treat bleeding disorders.

Faculty bios

Sebastian Cerdeña, PharmD, BCOP
Oncology Clinical Pharmacy Specialist
Barnes Jewish Hospital
St. Louis, Missouri 

Caitlyn L. Crawford, PharmD, BCOP
Clinical Hematology/Oncology Pharmacist
Atrium Wake Forest Baptist
Winston Salem, North Carolina

Sandra Cuellar, PharmD
Clinical Associate Professor and Clinical Oncology Pharmacist
UI Health/University of Illinois at Chicago College of Pharmacy
Chicago, Illinois 

Kathryn Dane, PharmD
Clinical Pharmacy Specialist
Benign Hematology and Cardiology
The Johns Hopkins Hospital
Baltimore, Maryland

David L. DeRemer, PharmD BCOP
Clinical Professor and Assistant Director of Experimental Therapeutics Group
University of Florida
Gainesville, Florida 

Sarah Maryon Hayes, PharmD, BCOP
Hematology/Oncology Clinical Pharmacy Specialist
North Memorial Health
Robbinsdale, Minnesota

Nada Alsuhebany, PharmD, BCOP*
Ashley L. Johns, PharmD, MS, BCOP*
Kayleigh Marx, PharmD, BCOP*
Kelsey Zielke, PharmD, BCPS, BCOP*

Janet Bramell, PharmD, BCPS, BCOP
Elisabeth Hebert, BPharm, M.Sc, BCOP
Jeanne Noe, PharmD, BCOP
Carol Peek, PharmD
Kristen Rychalsky, PharmD, BCPS, BCOP
Hope Schenk, PharmD, BCOP
Rachel Vaught, PharmD, BCOP

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support and the Accreditation Council for Pharmacy Education’s Standards for Commercial Support, ASHP requires that all individuals involved in the development of activity content disclose their relevant financial relationships. A person has a relevant financial relationship if the individual of his or her spouse/partner has a financial relationship (e.g. employee, consultant, research grant recipient, speakers bureau, or stockholder) in any amount occurring the in the last 12 months with a commercial interest whose products or series may be discussed in the educational activity content over which the individual has control. The existence of these relationships is provided for the information of participants and should not be assumed to have an adverse impact on the content. 

All faculty and planners for ACCP and ASHP education activities are qualified and selected by ACCP and ASHP required to disclose any relevant financial relationships with commercial interests. ACCP and ASHP identifies and resolves conflicts of interest prior to an individual’s participation in development of content for an educational activity. Anyone who refuses to disclose relevant financial relationships must be disqualified from any involvement with a continuing pharmacy education activity.

All other planners, presenters, reviewers, ACCP and ASHP staff and others with an opportunity to control content report no financial relationships relevant to this activity.

Activities which can be completed in any order. Each activity consists of audio, video, and/or PDFs and evaluations.  Learners must review all content and complete the evaluations to receive continuing pharmacy education credit for each activity. 

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity. 

These activities were developed by ASHP and ACCP.